JP2019515643A - 幹細胞分化剤のスクリーニング方法 - Google Patents

幹細胞分化剤のスクリーニング方法 Download PDF

Info

Publication number
JP2019515643A
JP2019515643A JP2018515676A JP2018515676A JP2019515643A JP 2019515643 A JP2019515643 A JP 2019515643A JP 2018515676 A JP2018515676 A JP 2018515676A JP 2018515676 A JP2018515676 A JP 2018515676A JP 2019515643 A JP2019515643 A JP 2019515643A
Authority
JP
Japan
Prior art keywords
optionally substituted
cancer
stem cells
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018515676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515643A5 (https=
Inventor
バンダッド，シンシア
モー，スコット
Original Assignee
ミネルバ バイオテクノロジーズ コーポレーション
ミネルバ バイオテクノロジーズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミネルバ バイオテクノロジーズ コーポレーション, ミネルバ バイオテクノロジーズ コーポレーション filed Critical ミネルバ バイオテクノロジーズ コーポレーション
Publication of JP2019515643A publication Critical patent/JP2019515643A/ja
Publication of JP2019515643A5 publication Critical patent/JP2019515643A5/ja
Priority to JP2021042947A priority Critical patent/JP7138207B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
JP2018515676A 2015-09-23 2016-09-23 幹細胞分化剤のスクリーニング方法 Pending JP2019515643A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021042947A JP7138207B2 (ja) 2015-09-23 2021-01-08 幹細胞分化剤のスクリーニング方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562222713P 2015-09-23 2015-09-23
US62/222,713 2015-09-23
PCT/US2016/053571 WO2017053886A2 (en) 2015-09-23 2016-09-23 Method of screening for agents for differentiating stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021042947A Division JP7138207B2 (ja) 2015-09-23 2021-01-08 幹細胞分化剤のスクリーニング方法

Publications (2)

Publication Number Publication Date
JP2019515643A true JP2019515643A (ja) 2019-06-13
JP2019515643A5 JP2019515643A5 (https=) 2019-11-07

Family

ID=58387520

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018515676A Pending JP2019515643A (ja) 2015-09-23 2016-09-23 幹細胞分化剤のスクリーニング方法
JP2021042947A Active JP7138207B2 (ja) 2015-09-23 2021-01-08 幹細胞分化剤のスクリーニング方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021042947A Active JP7138207B2 (ja) 2015-09-23 2021-01-08 幹細胞分化剤のスクリーニング方法

Country Status (8)

Country Link
US (2) US11931347B2 (https=)
EP (1) EP3352566A4 (https=)
JP (2) JP2019515643A (https=)
CN (2) CN113527289A (https=)
AU (2) AU2016326718B2 (https=)
CA (1) CA2999503A1 (https=)
IL (3) IL258314B (https=)
WO (1) WO2017053886A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019515643A (ja) 2015-09-23 2019-06-13 ミネルバ バイオテクノロジーズ コーポレーション 幹細胞分化剤のスクリーニング方法
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
EP3600451B1 (en) * 2017-03-29 2025-12-24 Minerva Biotechnologies Corporation Agents for differentiating stem cells and treating cancer
CN107892690A (zh) * 2017-11-30 2018-04-10 江苏杏睿生物科技有限公司 Fascaplysin的衍生物及制备方法与用途
WO2019126357A1 (en) * 2017-12-19 2019-06-27 Minerva Biotechnologies Corporation Agents for treating cancer and methods for identifying said agents
CN107880040A (zh) * 2017-12-22 2018-04-06 中国药科大学 一种四氢β－咔啉类衍生物及其制备方法与用途
CN113784962B (zh) 2019-02-27 2025-04-25 加利福尼亚大学董事会 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环
CA3183958A1 (en) * 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Methods for deriving dopaminergic neurons from pluripotent stem cells
KR20230028796A (ko) 2020-06-26 2023-03-02 미네르바 바이오테크놀로지 코포레이션 항-nme 항체 및 암 또는 암 전이의 치료 방법
TW202333668A (zh) 2021-12-15 2023-09-01 美商德利克斯醫療公司 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途
KR20250009592A (ko) 2022-04-12 2025-01-17 미네르바 바이오테크놀로지 코포레이션 항-가변 muc1* 항체 및 그의 용도
CN115521306B (zh) * 2022-09-26 2024-03-26 贵州大学 一种1,2,3,4-四氢-β-咔啉衍生物及其制备方法和应用
CN115594675B (zh) * 2022-11-02 2024-01-30 西安医学院 一种 β-卡巴林-肉桂酸骨架衍生物及制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009022104A1 (en) * 2007-08-13 2009-02-19 De Montfort University Fascaplysin derivatives and their use in the treatment of cancer
WO2014130741A2 (en) * 2013-02-20 2014-08-28 Minerva Biotechnologies Corporation Nme inhibitors and methods of using nme inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US7625697B2 (en) 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
JPH11512294A (ja) * 1995-09-01 1999-10-26 ラモット ユニヴァーシティー オーソリティ フォア アップライド リサーチ アンド インダストリアル ディヴェロプメント リミテッド 癌の治療、予防および発見を目的とする腫瘍細胞での蛋白ホスファターゼ２Ｃ−ＰＰ２Ｃα−発現の操作と検出
ES2175404T3 (es) * 1996-05-10 2002-11-16 Icos Corp Derivados de carbolina.
JP2006520326A (ja) * 2003-02-28 2006-09-07 ハワード フローリー インスティチュート オブ エクスペリメンタル フィジオロジー アンド メディシン 治療薬
CN1852974A (zh) * 2003-06-09 2006-10-25 密歇根大学董事会 用于治疗和诊断癌症的组合物和方法
ES2427166T3 (es) * 2003-06-23 2013-10-29 Ono Pharmaceutical Co., Ltd. Compuesto heterocíclico tricíclico novedoso
CN1910183A (zh) * 2004-01-23 2007-02-07 希龙公司 四氢咔啉化合物作为抗癌药
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
MXPA06010543A (es) 2004-03-15 2007-03-26 Ptc Therapeutics Inc Derivados de carbolina utiles en la inhibicion de la angiogenesis.
US20080064680A1 (en) * 2004-09-14 2008-03-13 Bamdad Cynthia C Methods for Diagnosis and Treatment of Cancer
DK1875244T3 (en) 2005-03-30 2019-04-29 Minerva Biotechnologies Corp Proliferation of MUC1-Expressing Cells
WO2007076055A2 (en) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
WO2008058037A1 (en) * 2006-11-03 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
CN101652469B (zh) * 2006-12-06 2014-04-16 米纳瓦生物技术公司 用于鉴定和操作细胞的方法
WO2009042815A1 (en) 2007-09-25 2009-04-02 Minerva Biotechnologies Corp. Methods for treatment of cancer
EP2274617A4 (en) * 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS
WO2009140260A2 (en) 2008-05-13 2009-11-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cancer stem cell immortalization
EP3228629A1 (en) * 2010-06-16 2017-10-11 Minerva Biotechnologies Corporation Reprogramming cancer cells
JP2012068225A (ja) 2010-08-25 2012-04-05 Fujifilm Corp 放射線画像撮影用グリッド及びその製造方法
EP2561888A1 (en) 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
EP2768945B1 (en) * 2011-10-17 2022-01-05 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
WO2014036654A1 (en) 2012-09-06 2014-03-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
TWI659210B (zh) * 2013-08-12 2019-05-11 Minerva Biotechnologies Corporation 加強腫瘤生長的方法
CN103880841B (zh) 2014-02-20 2016-04-13 南通大学 含有β-咔啉-3-酰亚肼基的HDAC抑制剂及其制备方法和用途
JP2019515643A (ja) 2015-09-23 2019-06-13 ミネルバ バイオテクノロジーズ コーポレーション 幹細胞分化剤のスクリーニング方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009022104A1 (en) * 2007-08-13 2009-02-19 De Montfort University Fascaplysin derivatives and their use in the treatment of cancer
WO2014130741A2 (en) * 2013-02-20 2014-08-28 Minerva Biotechnologies Corporation Nme inhibitors and methods of using nme inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NATH, S. ET AL., TRENDS IN MOLECULAR MEDICINE, vol. 20, no. 6, JPN6020028939, June 2014 (2014-06-01), pages 332 - 342, ISSN: 0004472842 *

Also Published As

Publication number Publication date
IL258314A (en) 2018-05-31
CN113527289A (zh) 2021-10-22
US20240307359A1 (en) 2024-09-19
US20180263964A1 (en) 2018-09-20
EP3352566A4 (en) 2019-07-31
IL287558B2 (en) 2023-02-01
EP3352566A2 (en) 2018-08-01
IL287558A (en) 2021-12-01
JP7138207B2 (ja) 2022-09-15
US11931347B2 (en) 2024-03-19
IL258314B (en) 2021-12-01
WO2017053886A2 (en) 2017-03-30
IL279941A (en) 2021-03-01
CA2999503A1 (en) 2017-03-30
AU2016326718B2 (en) 2022-12-15
AU2022275400B2 (en) 2024-07-11
IL279941B (en) 2021-12-01
IL287558B (en) 2022-10-01
WO2017053886A3 (en) 2017-06-08
JP2021119133A (ja) 2021-08-12
AU2016326718A1 (en) 2018-04-12
CN108513537A (zh) 2018-09-07
AU2022275400A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
JP7138207B2 (ja) 幹細胞分化剤のスクリーニング方法
US20200354331A1 (en) Icariin derivatives
JP2024023246A (ja) 幹細胞を分化し、癌を処置するための作用薬
KR20170132333A (ko) 글루타미나제 억제제에 의한 폐암의 치료
WO2019126357A1 (en) Agents for treating cancer and methods for identifying said agents
EP3749355B1 (en) Inhibitors of the notch transcriptional activation complex kinase ("nack") and methods for use of the same
HK40058056A (en) Method of screening for agents for differentiating stem cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210325